Physician profile
Simon S Rodriguez
NPI 1952512246
$8,818.81
in general payments reported to CMS, 2019-2025
38 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $374 · 2021: $1,123 · 2022: $2,445 · 2023: $1,630 · 2024: $1,446 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.76 |
| Education | $209.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,358.84 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,325.64 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $1,046.80 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $680.15 | 2021-2025 | |
| Horizon Therapeutics Plc | $595.49 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $558.52 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $368.77 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $349.54 | 2019-2025 | Jynarque |
| Amgen INC. | $349.24 | 2020-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.72 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $272.97 | 2019-2024 | Auryxia |
| Opko Pharmaceuticals, LLC | $236.68 | 2020-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $215.39 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $195.12 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $192.86 | 2023-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $170.03 | 2019-2024 | Ultomiris |
| Medtronic, INC. | $114.25 | 2022 | |
| Fresenius USA Marketing, INC. | $60.73 | 2021-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $58.82 | 2023-2025 | |
| Veloxis Pharmaceuticals, INC. | $35.40 | 2025 | Envarsus |
| Pfizer INC. | $31.62 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $30.69 | 2024 | Acthar |
| Melinta Therapeutics, LLC | $29.96 | 2024 | Rezzayo |
| E.R. Squibb & Sons, L.L.C. | $29.51 | 2021 | |
| Genzyme Corporation | $28.16 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.13 | 2023 | Gattex |
| Cormedix INC. | $24.15 | 2024 | Defencath |
| Dexcom, INC. | $23.80 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $22.44 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.47 | 2022 | |
| Scpharmaceuticals INC. | $16.04 | 2025 | |
| Amarin Pharma, INC. | $15.83 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.86 | 2023 | Inpefa |
| Lilly USA, LLC | $13.64 | 2023 | Mounjaro |
| Nxstage Medical, INC. | $12.81 | 2021 | |
| Outset Medical INC | $9.74 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.